# Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

> **NCT05184335** · PHASE3 · RECRUITING · sponsor: **Reviva Pharmaceuticals** · enrollment: 690 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Brilaroxazine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05184335
- **Lead sponsor:** Reviva Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-24
- **Primary completion:** 2025-02
- **Final completion:** 2025-02
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184335, "Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05184335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*